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Abstract
Crossover clinical trials can provide substantial benefits by eliminating inter-patient
variation from treatment comparisons and by allowing multiple observations of each
patient. They are particularly useful when sample sizes are necessarily small. These
advantages proved particularly valuable in an assessment of clot prevention in children
undergoing haemodialysis. Only small numbers of children are treated at any given
time in any single unit, but each patient is obliged to attend two or three times each
week, suggesting the use of a crossover trial with many periods. Standard crossover
trials described in the literature a) typically have fewer than 10 periods and b) are
based on a model of questionable applicability to this study. This paper describes the
derivation of an optimal crossover trial with 30 periods which was used to compare the
treatments using nine patients.
Key words: Crossover trial; Crossover design; optimal design; paediatric nephrology.
1 Introduction
Children undergoing regular haemodialysis for renal failure need to attend the dialysis unit
(DU) two or three times per week. On each visit the dialyser is connected to the patient’s
circulation. To achieve this the patient usually has a surgically inserted venous central line
which remains in place permanently and is accessed on each visit to the DU. During the
interdialytic period the blood in the lumen of the line may clot. Unclotting a line is a
time-consuming problem and if it happens regularly then the central line will have to be
re-sited. Re-siting is both unpleasant for the patient and undesirable, as it is a procedure
that cannot be repeated indefinitely because of the limited number of sites which can be
used for this purpose. For these patients failure to achieve reliable venous access has dire
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consequences. Consequently, a small amount of anticoagulant (a “lock”) is injected into the
lumen of the central line at the end of each dialysis session in order to prevent clotting. The
usual anticoagulant is heparin (H). This article is concerned with design issues that arose in
a trial to compare heparin with alteplase (A), an alternative anticoagulant.
The dialysis treatment of choice for children with renal failure is peritoneal dialysis, but there
are a few patients for whom this is unsuitable, or for whom peritoneal dialysis is no longer
viable. Consequently, in a paediatric population there are only a few children attending
for haemodialysis at any centre: fewer than ten patients in a UK regional centre at any
given time is typical. Moreover, differences in treatment protocols between centres mean
that a multicentre study would be difficult to run. However, each patient who does attend
the DU is obliged to do so three (or, for occasional patients, two) times a week. Therefore
information on the comparison between A and H can best be obtained using a crossover
design, as this allows each patient to provide numerous observations, and at the same time
improve the precision of the estimated comparison between A and H by eliminating inter-
patient differences. The trial will measure the weight of clot in the blood withdrawn from
the central line at the start of each dialysis session. As this withdrawal of blood is part of
the usual clinical procedure to flush the line prior to dialysis, it imposes no burden on the
patient and as such can repeated many times.
Numerous crossover designs are available in the literature (Jones and Kenward, 2003, chap-
ters 4 & 5) but designs with more than ten periods are unusual in most areas of application
and almost unheard of in clinical settings. Moreover, what optimality properties these de-
signs possess are usually based on one of a handful of rather general models which may not
be the most appropriate choice for the current trial. The next section considers the technical
issues which arise in developing a design for this study, in particular the choice of a realistic
statistical model for this application and its implications for design selection. In Section 3 an
optimal design is derived for this model and in Section 4 some practical issues are discussed.
2 Choice of design and statistical model
To avoid causing practical difficulties on the DU it was decided to run the trial for w weeks,
so for most patients a 3w-period design is required but for those patients who need to attend
only twice per week, a 2w-period design is needed. This is the first non-standard feature of
the design problem: almost all “off-the-shelf” designs assume that each experimental subject
is observed equally often.
The second issue is that most available designs assume that the response observed on subject
i in period j, yij, follows the model:
yij = µ+ ξi + πj + τd(i, j) + ǫij , (1)
where 1 ≤ i ≤ n and 1 ≤ j ≤ p. Here µ is a general mean; ξi is some form of subject
effect, either fixed or random; πj is the effect of period j; τt is the effect of treatment t and
d(i, j) is the treatment allocated to subject i in period j, and ǫij are independent residuals
with a common variance. More specialised designs specific to the crossover setting have been
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derived for a model which explicitly acknowledges the possibility of the effect of a treatment
carrying over to the following period, namely
yij = µ+ ξi + πj + τd(i, j) + γd(i,j−1) + ǫij . (2)
where γt is the carryover effect of t and we set γd(i, 0) = 0: see (Jones and Kenward, 2003,
chapters 4 and 5) for details.
For our purposes the former model (1) is more relevant because the effects of the antico-
agulants will not carry over to subsequent periods. This is because only a small quantity
of anticoagulant is used at the end of each dialysis session. The volume is just sufficient
to fill the lumen of the central line and it largely stays in situ until the following session.
Moreover, at the start of the next session the line is aspirated, thereby removing most of
the anticoagulant; any small amount left in the line will be flushed out in the course of the
dialysis. Systemic effects due to small quantities of anticoagulant diffusing from the lumen
into the circulation will be negligible because i) the volume of anticoagulant involved will be
very small compared with the volume of the circulation and ii) the agents will be metabolised
long before the subsequent dialysis session.
Optimal designs for model (1) are row-column designs such as Latin square and Youden
designs, in which each treatment occurs equally often on each subject and in each period
(Shah and Sinha, 1989, Chapter 4). These conditions are rather restrictive in that they
impose conditions on the divisibility of p and n by the number of treatments. Moreover,
they arise from the very general form of period effect allowed by (1), where a separate
parameter is specified for each period.
In the present application the condition that each treatment, i.e. A and H, should be applied
equally often to each patient is unlikely to be troublesome. However, having A and H occur
equally often in each period is potentially more troublesome to arrange. The model in (1)
goes back at least to animal feeding trials (Cochran et al., 1941) where the appropriateness
of the period effect would have been much clearer. Its widespread adoption in the theory
of crossover designs has often had a precautionary flavour - analysts feeling that designs
needed to be protected again the possible untoward influences of non-specific period effects
(Matthews, 1994a,b), rather than that there was any clear-cut reason for the form adopted
in (1).
In fact, the study of aspects of dialysis is an area where the inclusion of period effects in
the statistical model can be justified. As pointed out by Matthews and Hoenich (1994),
many variables which can be measured during or following dialysis will be affected by the
point in the dialysis cycle when the observation is made. Most DUs operate a cycle of
dialysis sessions whereby a patient attends on Mondays, Wednesdays and Fridays (or on
Tuesdays, Thursdays and Saturdays but for definiteness we will assume the former, as the
alternatives are equivalent). On Mondays, variables such as the size of clots, or the amount
of urea available for removal from the blood will have accumulated over the three days since
attending the previous Friday, so can be expected to be different from the corresponding
quantity on a Wednesday or Friday, as this will have accumulated over only two days.
We therefore decided to adopt the following model for the expected weight of clot aspirated
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from a patient i who attends the DU ℓ times per week. In period j = 1, . . . , ℓw.
E(yij) = τd(i, j) + πℓ(i, j) + ξi, (3)
where d(i, j) = 1 if H is allocated to patient i in period j and -1 if A is allocated. For
patients attending three times per week
π3(i, j) = π1, if j is a Monday
= π2, if j is a Wednesday (4)
= π3, if j is a Friday.
Note that the observation yij is the weight of clot aspirated following allocation of treatment
d(i, j) but this is only obtained when the lumen is aspirated at the following dialysis session.
Therefore, for example, the observation yi,Friday which relates to the treatment allocated on
the Friday, is not obtained until the following Monday. Given that the interval between
Wednesday and Friday is the same as that between Monday and Wednesday, a possible
simplification of (4) is to set π1 = π2. We do not adopt this slightly more prescriptive form
as it transpires that this extra restriction provides no important practical advantage in the
specification of the design.
For those patients required to attend only on Mondays and Fridays we replace π3(i, j) by
π2(i, j) to accommodate the different attendance schedule, namely
π2(i, j) = π4, if j is a Monday (5)
= π3, if j is a Friday.
The parameter π3 is common between π2(i, j) and π3(i, j) as both groups of patients attend
on Monday having attended on the preceding Friday.
The final aspect of the model which needs consideration is the residual term ǫij = yij −
E(yij). This represents the within-patient variation and these terms will be assumed to be
independent with common variance σ2. The assumption of independence is questionable
when each individual is observed serially over time: we will briefly consider the possible
effect of dependence on the design calculations in the next section. It is also possible that
the assumption of homoscedasticity will prove unfounded, although we would aim to address
such issues by suitable transformation of the yij.
3 Optimality calculations
We suppose that N3 patients dialysed three times per week and that N2 patients dialysed
twice weekly will be recruited, providing a total of m = 3wN3+2wN2 observations. The aim
is to determine the best treatment sequences to use to define the d(i, j). A good review of
this area can be found in Stufken (1996). There are a variety of optimality criteria which can
be used but because we are comparing only two treatments these all coincide and optimal
designs are chosen to minimise the variance of the estimator of τ .
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3.1 General conditions
In order to obtain an optimal design suppose that the design matrix, X , implied by (3) is
written as (A | B1 | B2) where B1 corresponds to the period parameters, B2 corresponds to
the patient parameters ξi and A is the m×1 matrix which describes the treatment allocation.
In the following we use ‘information matrix’ to denote the inverse of the dispersion matrix,
even though no likelihood is defined by the model in (1). If we write P(X) = X(XTX)−XT
for the orthogonal projection onto the column space of X and P⊥(X) = I − P(X), then
the information matrix for τ can be written as
I1 = σ
−2ATP⊥([B1 | B2])A (6)
where [B1 | B2] is X with the column for A omitted. Direct evaluation of this matrix is
cumbersome because the number of columns in B2 increases with the number of patients.
An alternative approach uses an identity for projection matrices
P
⊥([B1 | B2]) = P⊥(B1)−P(P⊥(B1)B2), (7)
which was first applied to crossover designs by Kunert (1983). The information matrix for
τ in the model which omits patient effects from (3) is
I2 = σ
−2ATP⊥(B1)A. (8)
Using (7) it can be seen that I2 − I1 ≥ 0 unless ATP(P⊥(B1)B2)A = 0, in which case
they coincide. Here A−B ≥ 0 would in general mean that A−B was positive semi-definite,
but in the present application it is a simple inequality as I1,I2 are scalars. This equation
requires that A should be orthogonal to the columns of P⊥(B1)B2, which amounts to:
ATB2 = A
T
P(B1)B2. (9)
Therefore, if we find a design which maximises the information for τ in the model with
patient effects omitted and if this design also obeys (9), then the design will be optimal for
the full model (3).
3.2 Detailed calculations
In the model (3) A is anm×1 vector, B1 is anm×4 matrix and B2 is anm×(N2+N3) matrix.
In order to use the results outlined above we need expressions for ATB2, A
TP(B1)B2 and
ATP⊥(B1)A.
ATB2 is a 1×(N2+N3) vector, where the ith element refers to patient i and is the number of
times patient i receives H minus the number of times they receive A. The matrix ATP(B1)B2
is a 1 × (N2 + N3) matrix where each element has one of two values: qTRP3 for patients
treated three times per week and qTRP2 for patients treated twice a week. Here
qT =
(
q3M q
3
W q
3
F + q
2
F q
2
M
)
,
where, e.g., qℓM is the number of times H was allocated on a Monday minus the number of
times A was allocated on that day among patients dialysed ℓ times per week: corresponding
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differences for Wednesdays and Fridays have the subscripts W and F respectively. Further
definitions and derivations are in the Appendix.
The results in the Appendix, specifically equations (10) and (11), can be combined to show
that the information on τ in the reduced model (8) is
σ−2ATP⊥(B1)A = σ
−2
(
m− qTRq)
= σ−2
[
m− 1
w
(
(q3M)
2
N3
+
(q3W )
2
N3
+
(q3F + q
2
F )
2
N3 +N2
+
(q2M)
2
N2
)]
.
A design with q = 0, i.e. with equal replication of A and H on Mondays and Wednesdays
within the thrice-weekly patients and equal replication on Mondays within the twice-weekly
patients and, in addition, with q3F+q
2
F = 0, will maximise A
TP⊥(B1)A. Such a design would
automatically mean that ATP(B1)B2 = 0. Therefore any such design for which A
TB2 also
vanishes, i.e. each patient receives A and H the same number of times, will be optimal for the
model (3). Although such designs could arise from cases where neither q2F nor q
3
F was zero,
in practice it will be easier to ensure q2F + q
3
F = 0 by looking for designs where q
3
F = q
2
F = 0.
3.3 Design Construction
An optimal design will provide an estimator of τ that has variance σ2/(w[3N3 + 2N2]) and
this can be used to determine the length of the trial. The number of patients of each type
(i.e. attending two- or three-times weekly) available for the study will be known at the
outset. If the usual requirements of a sample size calculation, namely an estimate of σ2,
and of the treatment difference to be detected, 2τ0, then the number of weeks, w, needed
to give a specified power and size for the associated hypothesis test can be calculated. In
the present application the precise length of the trial is not critical, so the construction of
suitable designs will be expedited if w is rounded up so that w is even.
A clinically important difference between H and A was thought to be 10mg, giving τ0 = 5,
and some pilot data suggested a planning estimate for σ of 22mg. For a two-sided 5%
test with 80% power this gives (τ0/σ)
√
m = 1.96 + 0.84 = 2.8, leading to m ≈ 152. At
the planning stage there were four patients being treated three times per week and two
twice-weekly, so m = 16w and hence a trial with w = 10, i.e. lasting 10 weeks, is indicated.
The task is to determine appropriate sequences so that the resulting design obeys the con-
ditions that ensure the design is optimal. An optimal design for patients who are treated
three times per week can be constructed as follows. Consider the set of four 3-sequences
S3 = {AAA,AAH,AHH,AHA}: these are all the sequences of As and Hs of length three
starting with an A. The dual of any element of S3 is the sequence with As and Hs inter-
changed. Any of these sequences could be used to specify the treatments to be allocated in
a particular week. For a trial with ten weeks we need to select ten of the sequences in an
appropriate way. We proceed in two stages. Suppose the sequences are written as in Table 1
with A-E allocated to the first five weeks and the corresponding lower-case labels to the last
five weeks. We randomly choose an element of S3 and assign this to be sequence A and then
assign the dual of A to a. Repeat for the remaining B-E. In the second stage, the sequences
A to e are randomly permuted - e.g. as in the second row of table 1.
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This construction ensures i) each patient receives each of A and H 3× (1
2
w) times and that
each of A and H is used equally often on each of the days Monday, Wednesday, Friday. Clearly
this method could be used for any even value of w. Design sequences for patients treated
twice-weekly can be constructed analogously, starting from the sequences S2 = {AA,AH}.
A design comprising arbitrary numbers of patients treated two- and three-times weekly
constructed according to this algorithm will give q = 0 and equal replication within each
patient and hence will be an optimal design.
A B C D E a b c d e
↓
Randomly permute
↓
C B d A b E c D a e
Table 1: Weekly sequences for the trial
3.4 Dependent errors
The error terms ǫij are assumed to be independent, even within patients. The nature of the
process under investigation in the trial, namely properties of a small volume of fluid in the
lumen of an intravenous line that is flushed with many times of its own volume between each
observation, makes this assumption less questionable than might often be the case with serial
observations. However, if a simple adaptation can make the design robust to dependence in
the error term, then it would be prudent to use it.
The optimal design of two-treatment crossover designs with autocorrelated error was ad-
dressed by Matthews (1987), who found that for a model with no carryover term γij, designs
with rapidly changing allocations were optimal if the autocorrelation in the residual term
were positive. For positive autocorrelation, and in the present application, this would suggest
that the sequence AHA and its dual are slightly preferable to AHH and AAH, and certainly
to be preferred to AAA, and its dual. The algorithm given in Section 3.3 did not specify
the probabilities with which elements of S3 are chosen. We therefore decided to choose the
elements of {AAA,AAH,AHH,AHA} with respective probabilities { 1
10
, 1
5
, 1
5
, 1
2
}. This gives
a preponderance of rapidly alternating treatments in the design, while maintaining a range
of sequences. For patients treated twice per week the elements of S2 can be chosen with
probabilities {1
5
, 4
5
}. A reasonable range of sequences is desirable if the investigator wishes
to leave open the possibility of performing a randomization analysis of the data, in addition
to a model-based analysis.
4 Data analysis and some practicalities
Although planning for the study assumed four patients treated three times per week and two
twice-weekly, by the time the trial started, seven patients treated thrice-weekly, i.e. N3 = 7
7
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Figure 1: Normal probability plots of the residuals from model (3)
and two treated twice weekly, N2 = 2, were available. Full details of the study are reported
in Gittins et al. (2007).
There were some difficulties in the conduct of the trial. The most important of these was that
although the allocation to the treatment for the final period was done correctly, confusion
on the DU meant that the corresponding observation of clot weight was missed for all thrice
weekly patients. That this observation was to have been made at the start of August, when
the junior medical staff change over, may have been relevant. In addition there are some
isolated discrepancies: patient 8, one of the twice-weekly patients, missed their final four
observations (three H, one A) due the availability of a kidney transplant. Patients 1, 2 and
7 fell short of the revised total of 29 observations: patient 2 missed three observations due
to holidays, while patients 1 and 7 missed one each due to errors on the DU. Although any
deviation from the planned trial is undesirable, given the complexity of the design this level
is probably no more than should be expected. While the omission of a few observations will
reduce the power of the study, the reasons for the missing observations should not induce
any noticeable bias. Moreover, the study was planned on the basis of N3 = 4, N2 = 2, but
in fact N3 = 7, N2 = 2 were recruited, so the power would in fact have been higher than
planned.
Fitting the model (3) gave an estimate of the mean semi-treatment difference, τˆ=2.79g,
P=0.13, 95% confidence interval (-0.79,6.37), indicating a higher mean weight of clot on
heparin compared with alteplase. A normal probability plot of residuals shown in Figure
1(a) indicates that the model assumptions were questionable. A randomization analysis
based on 2000 re-randomizations of the treatment allocation using the scheme outlined in
Section 3.3 gave P=0.123, confirming the model-based P-value.
The probability plot in Figure 1(a) indicates that the data are skewed. This is shown,
separately for each treatment, in Figure 2 where it is apparent that in a high proportion of
occasions (30% H, 50% A) no clot was retrieved from the central line. A natural response
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Figure 2: Histograms of clot weight by treatment
is to skewed data is to take logs of the observations but with so many zeroes we need to use
a transformation of the form log(yij + k). Inspection of the data showed that the range of
non-zero clot weights retrieved was 0.6g to 146g (H) and 0.7g to 114g (A). Rather than use a
formal approach to estimating k, we chose k = 0.1g. More formal approaches using a shifted
Box-Cox transformation suggested a log transformation with k ≈ 0.001g. The estimate of
the treatment effect (2τ , on log scale) becomes 0.830, P = 0.013, 95% (0.175,1.485) (k = 0.1)
and 1.440, P = 0.018, 95% (0.250,2.631) (k = 0.001). This sensitivity to k, while typical of
data with many zeroes, is clearly undesirable.
An alternative approach is to take the analysis in two stages. First the probability of a
clot-free sample is assessed, and then the mean weights when clot is present are analysed. In
both cases a generalized estimating equation (GEE) was used, with patient used to define the
clustering variable. The first analysis gave an odds ratio of clotting as 2.34 times larger on H
than A, P < 0.001, 95% confidence interval (1.24,4.42). The second analysis addressed the
considerable remaining skewness in the non-zero clot weights by fitting a GEE with gamma
variances and a log link. This indicated that mean clots weights were 1.86 times heavier
using H than A (P < 0.001), 95% confidence interval (1.45,2.39).
5 Discussion
This application required a crossover design with many more periods than is usually the case.
While multi-period designs are available from families of designs already in the literature,
these require balance across patients: for example by ensuring equal replication of treatments
at each period. They also required that each patient be treated an equal number of times.
In the present application the second of these requirements would have needed the trial
to be extended for the twice-weekly patients which, while possible, would have been very
inconvenient for the DU. Practical difficulties could arise with the requirement to balance
9
Heparin Alteplase
Patient No. of observations % no clot No. of observations % no clot
1 13 46 15 67
2 14 29 12 58
3 14 7 15 40
4 14 43 15 93
5 14 43 15 20
6 14 21 15 33
7 14 7 14 36
8 7 43 9 67
9 10 20 10 20
Table 2: Data by patient: patients 1 to 7 treated three times per week, patients 8 and 9
treated twice per week
over periods. Moreover, this would arise from the use of a model for period effects that is
unnecessarily general. The use of the model (3) tailored to the application means that an
optimal design can be constructed by ensuring that each patient follows a particular form
of sequence, with no requirement to balance across patients. This is a helpful feature when
implementing the design.
The optimality calculations made no distributional assumptions although it did make second-
order assumptions, namely that the residual terms were uncorrelated and had constant
variance. Even if these assumptions are untrue, randomization tests can provide a valid
test of the hypothesis of no treatment effect. In the event, the data proved to be rather
different from that anticipated, with many instances where no clot was formed, especially
when alteplase was the used as the anticoagulant. A model-based analysis assuming Normal
errors gave a P -value very similar to that obtained from a randomization test. However,
the conclusion of the analysis was substantially different if log(yij + k), rather that the clot
weights yij were analysed. This suggests that there was also substantial heteroscedasticity
in the data. Moreover, the analyses were sensitive to the value of k, a parameter poorly
estimated by the data. Analyses of data of this form will seldom be adequately summarised
by a single paramter such as a mean or median, so something similar to the two-stage method
used will usually be necessary.
A more difficult question to address is the extent to which the properties of the design depart
from optimal now that it is clear that the original assumptions are untenable. Optimal design
theory for crossover trials started with the model (2) and has developed by considering
departures from this model in terms of the form of the carryover treatment term and the
dependence structure of the residuals. There is no work on design theory for crossover
trials with other forms of outcome, such as a binary variable. Designs that are optimal for
the mixed binary and continuous outcome that we have pursued here would be extremely
challenging to determine.
Moreover, the real issue is not how far the optimal design for the known outcomes differs
from that used at the outset but could we have chosen a design that would have had good,
but not necessarily optimal properties for a range of assumptions about the outcome. There
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are many papers going back over many years, which derive designs which have good proper-
ties over a range of assumptions (Cook and Nachtsheim, 1982; DuMouchel and Jones, 1994),
including recent contributions which address the problems posed by generalized linear mod-
els (Woods et al., 2006; Dror and Steinberg, 2006). However, most of these contributions
address robustness to mis-specification of the linear predictor or of the link function, rather
than the distribution of the the outcome variable.
Although derived using optimal design theory, the present design might have been arrived
at by more general considerations of orthogonality. The design used in this study is optimal
because it ensures the treatment effect is orthogonal to the period and patient effects. Such a
property can be shown to have formal advantages when the outcomes are uncorrelated with
constance variance. However, the notion that each treatment occurs equally often on each
patient and on each treatment day, has more general appeal. However, rigorous confirmation
of the value of this design for the type of data that actually arose in this trial is elusive.
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Appendix
The matrices B2 and B1 are
B2 =
(
IN3 ⊗ 13w 0(2wN3, N2)
0(2wN2, N3) IN2 ⊗ 12w
)
=
(
IN3 ⊗ 13w 0
0 IN2 ⊗ 12w
)
where In is the n× n identity matrix and 1n is an n× 1 vector of ones, and 0(a, b) denotes
an a× b matrix of zeroes. Also
B1 =
(
P
Q
)
=
(
1wN3 ⊗ I3 0(3wN3, 1)
0(2wN2, 3) IwN2 ⊗K
)
where
K =
(
0 1
1 0
)
Therefore BT1 B1 = P
TP +QTQ can be written
(
wN3 ⊗ I3 0
0 0
)
+
(
0 0
0 wN2 ⊗KTK
)
= w


N3
N3
N3 +N2
N2

 (10)
noting that KTK = I2.
The product BT1 B2 is
(
P T QT
)(IN3 ⊗ 13w 0
0 IN2 ⊗ 12w
)
=
(
P T (IN3 ⊗ 13w) QT (IN2 ⊗ 12w)
)
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Evaluating this matrix requires calculation of products such as (1TwN3 ⊗ I3)(IN3 ⊗ 13w) and
this is made easier if we note that, e.g., 13w = 1w ⊗ 13. We then obtain
BT1 B2 = w

1TN3 ⊗
(
13
0
)
1TN2 ⊗

 00
12




To evaluate ATB1 let A
T = (AT3 A
T
2 ) where Aℓ is the part of A relating to patients undergoing
dialysis ℓ times per week. Then ATB1 = A
T
3 P + A
T
2Q and we then obtain
AT3 P =
(
q3M q
3
W q
3
F 0
)
and
AT2Q =
(
0 0 q2F q
2
M
)
.
Here
q3M = q
3
M(H)− q3M(A)
where q3M(H) is the number of times H is allocated on a Monday to a thrice-weekly patient,
and q3M (A) is the corresponding count for alteplase: q
3
W (·) and q3F (·) refer to Wednesdays
and Fridays, while q2X(Y ) are the corresponding quantities for patients who are dialysed
twice-weekly. It follows that
ATB1 =
(
q3M q
3
W q
3
F + q
2
F q
2
M
)
= qT , say. (11)
If we write R = w−1diag
(
N−13 N
−1
3 (N3 +N2)
−1 N−12
)
, then it follows that ATP(B1)B2
can be expressed as qTR(BT1 B2). Each element of A
TP(B1)B2 corresponds to a patient and
each element is either qTRP3 for thrice-weekly patients or q
TRP2 for twice weekly patients,
where
P3 =


1
1
1
0

 P2 =


0
0
1
1


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